CS217603B1 - Method of preparing compositions for dissolving renal calculi - Google Patents
Method of preparing compositions for dissolving renal calculi Download PDFInfo
- Publication number
- CS217603B1 CS217603B1 CS727556A CS755672A CS217603B1 CS 217603 B1 CS217603 B1 CS 217603B1 CS 727556 A CS727556 A CS 727556A CS 755672 A CS755672 A CS 755672A CS 217603 B1 CS217603 B1 CS 217603B1
- Authority
- CS
- Czechoslovakia
- Prior art keywords
- weight
- citrate
- parts
- magnesium
- citric acid
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 29
- 208000000913 Kidney Calculi Diseases 0.000 title claims abstract description 12
- 206010029148 Nephrolithiasis Diseases 0.000 title claims abstract description 12
- 238000000034 method Methods 0.000 title claims description 11
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims abstract description 11
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 claims abstract description 11
- 229910001425 magnesium ion Inorganic materials 0.000 claims abstract description 11
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 43
- -1 citrate ions Chemical class 0.000 claims description 15
- 229960004106 citric acid Drugs 0.000 claims description 14
- 239000001509 sodium citrate Substances 0.000 claims description 14
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 14
- 239000001508 potassium citrate Substances 0.000 claims description 13
- 229960002635 potassium citrate Drugs 0.000 claims description 13
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 claims description 13
- 235000011082 potassium citrates Nutrition 0.000 claims description 13
- 239000008187 granular material Substances 0.000 claims description 12
- 239000004337 magnesium citrate Substances 0.000 claims description 9
- 229960005336 magnesium citrate Drugs 0.000 claims description 9
- 235000002538 magnesium citrate Nutrition 0.000 claims description 9
- PLSARIKBYIPYPF-UHFFFAOYSA-H trimagnesium dicitrate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O PLSARIKBYIPYPF-UHFFFAOYSA-H 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- 239000000243 solution Substances 0.000 claims description 8
- 229910052783 alkali metal Inorganic materials 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 5
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 claims description 4
- 229910000288 alkali metal carbonate Inorganic materials 0.000 claims description 4
- 150000008041 alkali metal carbonates Chemical class 0.000 claims description 4
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 claims description 4
- 239000001354 calcium citrate Substances 0.000 claims description 4
- 239000008298 dragée Substances 0.000 claims description 4
- 150000002681 magnesium compounds Chemical class 0.000 claims description 4
- 235000013337 tricalcium citrate Nutrition 0.000 claims description 4
- YASYEJJMZJALEJ-UHFFFAOYSA-N Citric acid monohydrate Chemical compound O.OC(=O)CC(O)(C(O)=O)CC(O)=O YASYEJJMZJALEJ-UHFFFAOYSA-N 0.000 claims description 3
- 150000001860 citric acid derivatives Chemical class 0.000 claims description 3
- 229960002303 citric acid monohydrate Drugs 0.000 claims description 3
- 239000000839 emulsion Substances 0.000 claims description 3
- UEGPKNKPLBYCNK-UHFFFAOYSA-L magnesium acetate Chemical compound [Mg+2].CC([O-])=O.CC([O-])=O UEGPKNKPLBYCNK-UHFFFAOYSA-L 0.000 claims description 3
- 239000011654 magnesium acetate Substances 0.000 claims description 3
- 235000011285 magnesium acetate Nutrition 0.000 claims description 3
- 229940069446 magnesium acetate Drugs 0.000 claims description 3
- 239000000395 magnesium oxide Substances 0.000 claims description 3
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 claims description 3
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 claims description 3
- 239000000725 suspension Substances 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- AEDORKVKMIVLBW-BLDDREHASA-N 3-oxo-3-[[(2r,3s,4s,5r,6r)-3,4,5-trihydroxy-6-[[5-hydroxy-4-(hydroxymethyl)-6-methylpyridin-3-yl]methoxy]oxan-2-yl]methoxy]propanoic acid Chemical compound OCC1=C(O)C(C)=NC=C1CO[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](COC(=O)CC(O)=O)O1 AEDORKVKMIVLBW-BLDDREHASA-N 0.000 claims description 2
- 239000003513 alkali Substances 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 229940064321 magnesium oxide 100 mg Drugs 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 229940089782 pyridoxine hydrochloride 5 mg Drugs 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- 239000011782 vitamin Substances 0.000 claims 4
- 229940088594 vitamin Drugs 0.000 claims 4
- 235000013343 vitamin Nutrition 0.000 claims 4
- 229930003231 vitamin Natural products 0.000 claims 4
- 150000003722 vitamin derivatives Chemical class 0.000 claims 4
- 150000004649 carbonic acid derivatives Chemical class 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000007788 liquid Substances 0.000 abstract description 3
- 239000007787 solid Substances 0.000 abstract description 3
- 239000004480 active ingredient Substances 0.000 abstract 2
- RBCOYOYDYNXAFA-UHFFFAOYSA-L (5-hydroxy-4,6-dimethylpyridin-3-yl)methyl phosphate Chemical compound CC1=NC=C(COP([O-])([O-])=O)C(C)=C1O RBCOYOYDYNXAFA-UHFFFAOYSA-L 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 239000008203 oral pharmaceutical composition Substances 0.000 abstract 1
- 239000008024 pharmaceutical diluent Substances 0.000 abstract 1
- DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 239000004575 stone Substances 0.000 description 13
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 8
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 6
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 229940116269 uric acid Drugs 0.000 description 6
- 235000013877 carbamide Nutrition 0.000 description 5
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- 239000004202 carbamide Substances 0.000 description 4
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 4
- 235000005979 Citrus limon Nutrition 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 239000011764 pyridoxine hydrochloride Substances 0.000 description 3
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 description 3
- 229960004172 pyridoxine hydrochloride Drugs 0.000 description 3
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 244000131522 Citrus pyriformis Species 0.000 description 2
- 208000009911 Urinary Calculi Diseases 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N Vitamin B6 Natural products CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 201000001883 cholelithiasis Diseases 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 2
- 239000001095 magnesium carbonate Substances 0.000 description 2
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 2
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 2
- 229960001790 sodium citrate Drugs 0.000 description 2
- 208000008281 urolithiasis Diseases 0.000 description 2
- 239000011726 vitamin B6 Substances 0.000 description 2
- 235000019158 vitamin B6 Nutrition 0.000 description 2
- 229940011671 vitamin b6 Drugs 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 244000248349 Citrus limon Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 229920003091 Methocel™ Polymers 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- QXDMQSPYEZFLGF-UHFFFAOYSA-L calcium oxalate Chemical compound [Ca+2].[O-]C(=O)C([O-])=O QXDMQSPYEZFLGF-UHFFFAOYSA-L 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000007931 coated granule Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- DKXRQYWYEBEXRA-UHFFFAOYSA-J dimagnesium 3-carboxy-3,5-dihydroxy-5-oxopentanoate 2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [Mg++].[Mg++].OC(=O)CC(O)(CC([O-])=O)C(O)=O.OC(CC([O-])=O)(CC([O-])=O)C([O-])=O DKXRQYWYEBEXRA-UHFFFAOYSA-J 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000000576 food coloring agent Substances 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- HHLFWLYXYJOTON-UHFFFAOYSA-N glyoxylic acid Chemical compound OC(=O)C=O HHLFWLYXYJOTON-UHFFFAOYSA-N 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- 150000003891 oxalate salts Chemical class 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229960003975 potassium Drugs 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 239000011253 protective coating Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 150000003672 ureas Chemical class 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/08—Oxides; Hydroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/10—Carbonates; Bicarbonates
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Inorganic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HUCI1185A HU165181B (enrdf_load_stackoverflow) | 1971-11-08 | 1971-11-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CS217603B1 true CS217603B1 (en) | 1983-01-28 |
Family
ID=10994422
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CS727556A CS217603B1 (en) | 1971-11-08 | 1972-11-08 | Method of preparing compositions for dissolving renal calculi |
Country Status (9)
| Country | Link |
|---|---|
| AT (1) | AT332531B (enrdf_load_stackoverflow) |
| CA (1) | CA978479A (enrdf_load_stackoverflow) |
| CS (1) | CS217603B1 (enrdf_load_stackoverflow) |
| DD (1) | DD100631A1 (enrdf_load_stackoverflow) |
| DE (1) | DE2252665A1 (enrdf_load_stackoverflow) |
| GB (1) | GB1403900A (enrdf_load_stackoverflow) |
| HU (1) | HU165181B (enrdf_load_stackoverflow) |
| IL (1) | IL40685A (enrdf_load_stackoverflow) |
| SU (1) | SU1009467A1 (enrdf_load_stackoverflow) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2826642C2 (de) | 1978-06-19 | 1987-04-23 | Dr. Madaus & Co, 5000 Köln | Orales Urolithiasismittel |
| DE3046580A1 (de) * | 1980-12-11 | 1982-07-01 | Leskovar, Peter, Dr.-Ing., 8000 München | Harnsteinaufloesende mittel |
| DE3728814A1 (de) * | 1987-08-28 | 1989-03-30 | Lentia Gmbh | Loesung zur anwendung als spuelfluessigkeit in der zerstoerung von koerperfremden ablagerungen in menschlichen und tierischen geweben oder koerperhohlraeumen |
| JP2545479B2 (ja) * | 1989-02-07 | 1996-10-16 | ミッション ファーマカル カンパニー，インコーポレーテッド | 医薬組成物 |
| CA1326040C (en) * | 1989-11-16 | 1994-01-11 | Neill B. Walsdorf | Magnesium-potassium citrate |
| DE4409949C2 (de) * | 1994-03-23 | 1996-11-21 | Madaus Ag | Verwendung von Calcium-Alkalicitraten zur Prophylaxe und Behandlung degenerativer Erkrankungen des Knochengerüstes |
| DE10028167B4 (de) * | 2000-06-09 | 2004-02-19 | Storch, Rüdiger, Dr. | Verwendung von Calciumsalzen zur Entgegenwirkung der Bildung von Oxalatharnsteinen |
| US8603989B2 (en) | 2008-05-22 | 2013-12-10 | Bristol-Myers Squibb Company | Method for treating and preventing kidney stones employing an SGLT2 inhibitor and composition containing same |
| FR2967578B1 (fr) | 2010-11-18 | 2012-12-28 | Advicenne Pharma | Composition pharmaceutique comportant des sels de citrate et de bicarbonate, et son utilisation pour le traitement de la cystinurie |
| FR2967576B1 (fr) * | 2010-11-18 | 2013-07-12 | Advicenne Pharma | Composition pharmaceutique comprenant du sel precurseur du cycle de krebs, en particulier du sel de citrate, et son utilisation comme medicament |
| CA2906907C (en) * | 2013-03-15 | 2021-04-13 | New York University | Citrate containing beverage |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3328304A (en) * | 1964-07-31 | 1967-06-27 | Guardian Chemical Corp | Chelating agents and methods for their manufacture |
| FR2019261A1 (en) * | 1969-03-19 | 1970-07-03 | Melon Jean Marie | Treatment of oxalic lithiase with succinic - acid and its derivs |
-
1971
- 1971-11-08 HU HUCI1185A patent/HU165181B/hu unknown
-
1972
- 1972-10-27 DE DE2252665A patent/DE2252665A1/de active Granted
- 1972-10-27 IL IL40685A patent/IL40685A/en unknown
- 1972-10-31 AT AT925372A patent/AT332531B/de not_active IP Right Cessation
- 1972-11-02 DD DD166641A patent/DD100631A1/xx unknown
- 1972-11-02 GB GB5049572A patent/GB1403900A/en not_active Expired
- 1972-11-04 SU SU721846969A patent/SU1009467A1/ru active
- 1972-11-07 CA CA155,789A patent/CA978479A/en not_active Expired
- 1972-11-08 CS CS727556A patent/CS217603B1/cs unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AT332531B (de) | 1976-10-11 |
| HU165181B (enrdf_load_stackoverflow) | 1974-07-27 |
| CA978479A (en) | 1975-11-25 |
| SU1009467A1 (ru) | 1983-04-07 |
| IL40685A (en) | 1976-08-31 |
| DE2252665C2 (enrdf_load_stackoverflow) | 1987-09-10 |
| DD100631A1 (enrdf_load_stackoverflow) | 1973-10-05 |
| GB1403900A (en) | 1975-08-28 |
| IL40685A0 (en) | 1972-12-29 |
| DE2252665A1 (de) | 1973-05-10 |
| ATA925372A (de) | 1976-01-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0557065B1 (en) | Spheroid formulation | |
| CA1040532A (en) | Process for producing solid bismuth-containing pharmaceutical compositions | |
| CA1135190A (en) | Effervescent analgesic powder | |
| KR100311576B1 (ko) | 경구투여용 항균성 조성물 | |
| US6620432B2 (en) | Phenytoin sodium pharmaceutical compositions | |
| EP0361680A2 (en) | Morphine-containing composition | |
| US5460829A (en) | Pharmaceutical compositions based on ebastine or analogues thereof | |
| CS217603B1 (en) | Method of preparing compositions for dissolving renal calculi | |
| CZ289304B6 (cs) | Farmaceutický prostředek ve formě efervescentních práąků nebo tablet, farmaceutický přípravek a způsob přípravy tohoto přípravku | |
| DE69010563T3 (de) | Wässrige Granulierungslösung und Verfahren zur Tablettengranulierung. | |
| US3865935A (en) | Tableting of erythromycin base | |
| FI86799B (fi) | Foerfarande foer framstaellning av skumbara blandningar. | |
| SK33096A3 (en) | Effervescent granulated material and method for its preparation | |
| KR100351193B1 (ko) | 아세틸살리실산메토클로프라미드화합물로구성된활성성분을갖는산제제조용조성물 | |
| US5004651A (en) | Stabilizing system for solid dosage forms | |
| EP1429748B1 (en) | Solid compositions comprising ramipril | |
| CA1201923A (en) | Acesulfam-containing compositions, tablets on the basis thereof and process for the manufacture of these tablets | |
| US4190655A (en) | Amiloride citrate | |
| US4076804A (en) | Erythromycin therapy | |
| PL177607B1 (pl) | Tabletka o opóźnionym uwalnianiu zawierająca sól sodową diklofenaku | |
| US5935603A (en) | Water soluble powder form compositions and their applications thereof | |
| US6060498A (en) | Composition containing antitumor agent | |
| TR201610368A2 (tr) | Geli̇şti̇ri̇lmi̇ş çözünme hizina sahi̇p si̇tagli̇pti̇n fosfat anhi̇drus formülasyonlari | |
| JP2003515553A (ja) | 発泡性ヒスタミンｈ２アンタゴニスト組成物 | |
| US2538092A (en) | Water-soluble sulfaquinoxaline tablet |